| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ben Wielockx | Q42574433 |
| P2093 | author name string | Sundary Sormendi | |
| P2860 | cites work | Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells | Q21133953 |
| Targeting aspartate aminotransferase in breast cancer | Q22000773 | ||
| Identification of small molecule inhibitors of pyruvate kinase M2 | Q22001512 | ||
| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity | Q24302129 | ||
| Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. | Q39321728 | ||
| A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. | Q39332797 | ||
| Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. | Q39372905 | ||
| HIF prolyl hydroxylase-2 inhibition diminishes tumor growth through matrix metalloproteinase-induced TGFβ activation | Q39392726 | ||
| Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. | Q39425252 | ||
| Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis | Q39596455 | ||
| Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling | Q39690768 | ||
| Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice | Q39699461 | ||
| Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses | Q39709758 | ||
| Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model | Q39723159 | ||
| Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line | Q39750823 | ||
| Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1 | Q24304533 | ||
| Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer | Q24314720 | ||
| Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance | Q24329133 | ||
| Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1 | Q24336199 | ||
| The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism | Q24337667 | ||
| Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 | ||
| Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism | Q24611305 | ||
| Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment | Q24620228 | ||
| Links between metabolism and cancer | Q24626229 | ||
| HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia | Q24671941 | ||
| Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation | Q24682128 | ||
| The myofibroblast: one function, multiple origins | Q24683749 | ||
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Q26744395 | ||
| Hypoxia and metabolic adaptation of cancer cells | Q26774856 | ||
| Overcoming T cell exhaustion in infection and cancer | Q26829885 | ||
| Metabolic reprogramming and metabolic dependency in T cells | Q26864319 | ||
| Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids | Q26996516 | ||
| Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment | Q27023678 | ||
| HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression | Q27025886 | ||
| Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis | Q27671695 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Neutrophil extracellular traps kill bacteria | Q27860996 | ||
| PHD2: from hypoxia regulation to disease progression | Q28069316 | ||
| The ever-expanding role of HIF in tumour and stromal biology | Q28079015 | ||
| Metabolic Reprogramming of Immune Cells in Cancer Progression | Q28081682 | ||
| Metabolic pathways promoting cancer cell survival and growth | Q28086940 | ||
| Inhibition of T cell proliferation by macrophage tryptophan catabolism | Q28142922 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| RETRACTED: Lysyl oxidase is essential for hypoxia-induced metastasis | Q28236828 | ||
| Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step. | Q33987684 | ||
| Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation | Q34028645 | ||
| Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages | Q34044797 | ||
| Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression | Q34168497 | ||
| Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. | Q34200930 | ||
| The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation | Q34242691 | ||
| HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment | Q34243443 | ||
| mTOR inhibitors in cancer therapy. | Q34248443 | ||
| M1 and M2 Macrophages: Oracles of Health and Disease | Q34328890 | ||
| Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes | Q34411361 | ||
| Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. | Q34412152 | ||
| Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. | Q34429912 | ||
| Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. | Q34538613 | ||
| Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13 | Q34541778 | ||
| Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer | Q34592559 | ||
| Mitochondria as signaling organelles in the vascular endothelium | Q34600173 | ||
| Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission | Q34611836 | ||
| Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. | Q34626763 | ||
| ATP citrate lyase inhibition can suppress tumor cell growth | Q34651116 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase | Q34687185 | ||
| Lipoprotein lipase links dietary fat to solid tumor cell proliferation. | Q34779246 | ||
| Targeting mitochondrial glutaminase activity inhibits oncogenic transformation | Q34807996 | ||
| Hypoxia and the extracellular matrix: drivers of tumour metastasis | Q34820282 | ||
| Peroxisomal lipid synthesis regulates inflammation by sustaining neutrophil membrane phospholipid composition and viability. | Q34871541 | ||
| Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors | Q34913785 | ||
| Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress | Q34978574 | ||
| GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells | Q34983887 | ||
| Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells | Q35052425 | ||
| Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo | Q35065823 | ||
| HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells | Q35102340 | ||
| A novel small molecule antagonist of choline kinase-α that simultaneously suppresses MAPK and PI3K/AKT signaling | Q35106366 | ||
| Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation | Q35242438 | ||
| PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation | Q35311785 | ||
| Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. | Q35404457 | ||
| Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes | Q39760366 | ||
| Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling | Q39783619 | ||
| The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. | Q39876494 | ||
| Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis | Q40002274 | ||
| A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction | Q40012089 | ||
| Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth | Q40105523 | ||
| Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells | Q40120007 | ||
| Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia | Q40244028 | ||
| Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. | Q40345618 | ||
| Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. | Q40362310 | ||
| Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). | Q40582648 | ||
| R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis | Q40654818 | ||
| BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. | Q40695052 | ||
| A Metabolic Shift toward Pentose Phosphate Pathway Is Necessary for Amyloid Fibril- and Phorbol 12-Myristate 13-Acetate-induced Neutrophil Extracellular Trap (NET) Formation | Q40710845 | ||
| Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells | Q41427795 | ||
| Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression | Q41437712 | ||
| Metabolic requirements for neutrophil extracellular traps formation. | Q41578654 | ||
| HIF1α and metabolic reprogramming in inflammation. | Q41678886 | ||
| De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. | Q41716248 | ||
| The emerging role of fumarate as an oncometabolite | Q42255812 | ||
| The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas | Q42511450 | ||
| The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 | ||
| Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. | Q42874599 | ||
| IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice | Q44259082 | ||
| TSC2 regulates VEGF through mTOR-dependent and -independent pathways | Q44574474 | ||
| Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses | Q45020410 | ||
| Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice | Q45111063 | ||
| Disrupting glucose-6-phosphate isomerase fully suppresses the "Warburg effect" and activates OXPHOS with minimal impact on tumor growth except in hypoxia | Q45205976 | ||
| Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. | Q45973092 | ||
| TCR engagement increases hypoxia-inducible factor-1 alpha protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells | Q46535400 | ||
| Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations | Q46575022 | ||
| Premature senescence of human endothelial cells induced by inhibition of glutaminase. | Q46720253 | ||
| Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin | Q46917157 | ||
| Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer | Q47888215 | ||
| Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. | Q50784960 | ||
| Neutrophil Extracellular Traps Accumulate in Peripheral Blood Vessels and Compromise Organ Function in Tumor-Bearing Animals. | Q50852930 | ||
| Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells | Q50889342 | ||
| Mechanisms of hypoxia-mediated immune escape in cancer. | Q51688583 | ||
| A reaction-diffusion model of cancer invasion. | Q52287271 | ||
| Glutaminolysis activates Rag-mTORC1 signaling. | Q52301079 | ||
| Timeline: Chemotherapy and the war on cancer. | Q53313789 | ||
| Differential regulation of iron homeostasis during human macrophage polarized activation. | Q53735318 | ||
| Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype | Q56942373 | ||
| Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells | Q67518356 | ||
| Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy | Q74615771 | ||
| Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma | Q80768403 | ||
| Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells | Q81098044 | ||
| Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation | Q84291714 | ||
| Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis | Q84595151 | ||
| A critical role for citrate metabolism in LPS signalling | Q84828552 | ||
| M-CSF from Cancer Cells Induces Fatty Acid Synthase and PPARβ/δ Activation in Tumor Myeloid Cells, Leading to Tumor Progression | Q86891684 | ||
| An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor | Q28249782 | ||
| Role of PFKFB3-driven glycolysis in vessel sprouting | Q28295875 | ||
| Hypoxia in cancer: significance and impact on clinical outcome | Q28298305 | ||
| HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia | Q28300406 | ||
| Regulation of cancer cell metabolism | Q28303890 | ||
| Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFβ | Q28307901 | ||
| The Intercellular Metabolic Interplay between Tumor and Immune Cells | Q28391079 | ||
| Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies | Q28393381 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells | Q28504783 | ||
| Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression | Q28646286 | ||
| Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming | Q28771755 | ||
| The biology of cancer: metabolic reprogramming fuels cell growth and proliferation | Q29547301 | ||
| The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth | Q29547680 | ||
| Fibroblasts in cancer | Q29547753 | ||
| Regulation of immune responses by L-arginine metabolism | Q29614284 | ||
| Activation of a metabolic gene regulatory network downstream of mTOR complex 1 | Q29615179 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis | Q29615683 | ||
| Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia | Q29616650 | ||
| Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity | Q29616651 | ||
| The LKB1-AMPK pathway: metabolism and growth control in tumour suppression | Q29617506 | ||
| Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing | Q29617570 | ||
| HIF-1alpha is essential for myeloid cell-mediated inflammation | Q29617581 | ||
| Otto Warburg's contributions to current concepts of cancer metabolism | Q29617601 | ||
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate | Q29617612 | ||
| Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN | Q29619346 | ||
| The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes | Q29619577 | ||
| Neutrophils in the activation and regulation of innate and adaptive immunity | Q29620082 | ||
| Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 | ||
| Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice | Q30080001 | ||
| LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells | Q30313865 | ||
| Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity | Q30406101 | ||
| Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis | Q30541882 | ||
| ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. | Q30574383 | ||
| Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization | Q30579125 | ||
| Glucose-6-phosphate dehydrogenase overexpression decreases endothelial cell oxidant stress and increases bioavailable nitric oxide | Q30890753 | ||
| Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines | Q31034514 | ||
| The genomic analysis of lactic acidosis and acidosis response in human cancers | Q33389864 | ||
| A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines | Q33431136 | ||
| Fatty acid carbon is essential for dNTP synthesis in endothelial cells | Q35548351 | ||
| Tumor-infiltrating neutrophils in pancreatic neoplasia | Q35583287 | ||
| Reductive carboxylation supports growth in tumour cells with defective mitochondria. | Q35683311 | ||
| TCR-Signaling Events in Cellular Metabolism and Specialization | Q35693169 | ||
| Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome | Q35764135 | ||
| Targeting AMPK for cancer prevention and treatment | Q35781311 | ||
| AMP-activated protein kinase is dispensable for maintaining ATP levels and for survival following inhibition of glycolysis, but promotes tumour engraftment of Ras-transformed fibroblasts | Q35828452 | ||
| Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes | Q35858012 | ||
| The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity | Q35880387 | ||
| Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis | Q35884610 | ||
| Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success | Q35906539 | ||
| Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. | Q36054460 | ||
| Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 | ||
| Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells | Q36304128 | ||
| Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis | Q36327483 | ||
| Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma | Q36342398 | ||
| Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma | Q36403544 | ||
| ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. | Q36435476 | ||
| G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts | Q36481702 | ||
| A CXCL1 paracrine network links cancer chemoresistance and metastasis | Q36482032 | ||
| Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth | Q36545664 | ||
| Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model | Q36615128 | ||
| Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. | Q36639793 | ||
| Metabolic regulation of T lymphocytes | Q36711431 | ||
| Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. | Q36793719 | ||
| Arginine and immunity | Q36826900 | ||
| Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. | Q36850905 | ||
| Deconvoluting the context-dependent role for autophagy in cancer | Q36876716 | ||
| Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress | Q36902914 | ||
| Hypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia | Q36941109 | ||
| Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor | Q36941301 | ||
| Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer | Q37024512 | ||
| Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives | Q37118164 | ||
| Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer | Q37120167 | ||
| The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. | Q37126990 | ||
| Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis | Q37175153 | ||
| Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis | Q37271066 | ||
| Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. | Q37325176 | ||
| Prolyl hydroxylases as regulators of cell metabolism. | Q37368345 | ||
| Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. | Q37489023 | ||
| Interdependence of hypoxic and innate immune responses | Q37586121 | ||
| T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming | Q37701913 | ||
| Targeting metabolic transformation for cancer therapy. | Q37714309 | ||
| Control of immune response by amino acid metabolism | Q37773432 | ||
| From vessel sprouting to normalization: role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. | Q37802125 | ||
| Targeting cancer metabolism: a therapeutic window opens | Q37924094 | ||
| mTOR signaling pathway and mTOR inhibitors in cancer therapy | Q38004213 | ||
| mTOR, metabolism, and the regulation of T-cell differentiation and function | Q38034265 | ||
| Hypoxia-inducible factors as key regulators of tumor inflammation | Q38051286 | ||
| How cancer metabolism is tuned for proliferation and vulnerable to disruption | Q38059777 | ||
| Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes | Q38064101 | ||
| Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force | Q38065324 | ||
| Metabolism of inflammation limited by AMPK and pseudo-starvation | Q38074586 | ||
| Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer | Q38080837 | ||
| PKM2 contributes to cancer metabolism | Q38186334 | ||
| Hypoxia and hypoxia inducible factors in tumor metabolism | Q38186340 | ||
| Th17 cells in cancer: the ultimate identity crisis. | Q38225542 | ||
| Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment | Q38246724 | ||
| Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells | Q38366558 | ||
| The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts | Q38847144 | ||
| In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation | Q39030433 | ||
| Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells. | Q39117748 | ||
| Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. | Q39149779 | ||
| PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. | Q39193337 | ||
| Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay | Q39304697 | ||
| Molecular mechanisms of neutrophil dysfunction in glycogen storage disease type Ib. | Q33556944 | ||
| PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation | Q33569771 | ||
| Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 | ||
| Succinate is an inflammatory signal that induces IL-1β through HIF-1α. | Q33652731 | ||
| Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol | Q33691999 | ||
| Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation | Q33705060 | ||
| Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells | Q33707270 | ||
| Quiescent fibroblasts exhibit high metabolic activity. | Q33737849 | ||
| The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function | Q33838591 | ||
| Loss of fibroblast HIF-1α accelerates tumorigenesis. | Q33874288 | ||
| Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis | Q33914549 | ||
| Quantitative flux analysis reveals folate-dependent NADPH production. | Q33924205 | ||
| Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells | Q33930109 | ||
| Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment | Q33955139 | ||
| Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism | Q33965102 | ||
| Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state | Q33968008 | ||
| Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes | Q33978763 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oxygen | Q629 |
| neoplasm | Q1216998 | ||
| tumor microenvironment | Q1786433 | ||
| hypoxia-inducible factor-proline dioxygenase | Q3818007 | ||
| tumor hypoxia | Q7852677 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 40 | |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment. | |
| P478 | volume | 9 |
| Q64890762 | A novel method to establish glucocorticoid resistant acute lymphoblastic leukemia cell lines. |
| Q57053012 | BHLHE40 confers a pro-survival and pro-metastatic phenotype to breast cancer cells by modulating HBEGF secretion |
| Q90218759 | Cancer Stem Cells in Pheochromocytoma and Paraganglioma |
| Q92361178 | Fatal Alliance of Hypoxia-/HIF-1α-Driven Microenvironmental Traits Promoting Cancer Progression |
| Q90163228 | Gene Therapy in Cancer Treatment: Why Go Nano? |
| Q92361171 | Hypoxia Compromises Anti-Cancer Immune Responses |
| Q99711542 | Hypoxia Induces Mitochondrial Defect That Promotes T Cell Exhaustion in Tumor Microenvironment Through MYC-Regulated Pathways |
| Q102141796 | Metastasis: crosstalk between tissue mechanics and tumour cell plasticity |
| Q89587258 | Microenvironment in Cardiac Tumor Development: What Lies Beyond the Event Horizon? |
| Q99632062 | Modulating barriers of tumor microenvironment through nanocarrier systems for improved cancer immunotherapy: a review of current status and future perspective |
| Q92556947 | NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer |
| Q93048600 | Nanotheranostics Targeting the Tumor Microenvironment |
| Q91927508 | Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes |
| Q90697892 | Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape |
| Q92800381 | Targeting Angiogenesis With Peptide Vaccines |
| Q64259998 | Targeting Tumor Microenvironment for Cancer Therapy |
| Q90194802 | Trends and Challenges in Tumor Anti-Angiogenic Therapies |
Search more.